Miniatura

Fitxers

17588359211019672.pdf (903.97 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-01-01

Llicència de publicació

cc by-nc (c) Jimenez Fonseca, Paula et al, 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/179950

External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1177/17588359211019672

Resum

Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III trials, many clinicians administer trastuzumab with alternative regimens. One meta-analysis suggests that substituting cisplatin for oxaliplatin might lead to greater efficacy and less toxicity. Methods: 594 patients with HER2-positive gastroesophageal adenocarcinoma were recruited from the AGAMENON-SEOM registry. The objective was to evaluate the external validity of clinical trials with chemotherapy and trastuzumab. Results: The regimens used in at least 5% of the patients were XP (27%), oxaliplatin and capecitabine (CAPOX) (26%), oxaliplatin and 5-fluorouracil (FOLFOX) (14%), FP (14%), triplet with anthracycline/docetaxel (7%), and carboplatin-FU (5%). Median exposure to trastuzumab was longer with FOLFOX (11.4 months, 95% CI, 9.1-21.0) versus ToGA regimens (7.5, 6.4-8.5), p < 0.001. Patients with HER2-IHC 3+ cancers had higher response rates than those with IHC 2+/FISH+, odds-ratio 1.97 (95% CI, 1.25-3.09). The results achieved with CAPOX-trastuzumab were comparable to those attained with ToGA regimens. FOLFOX-trastuzumab was superior to ToGA schemes in terms of overall survival (OS), with a greater magnitude of effect in IHC 2+/FISH+ tumors (HR 0.47, 0.24-0.92) compared with IHC 3+ (HR 0.69, 0.49-0.96), and in diffuse (HR 0.37, 0.20-0.69) versus intestinal-type tumors (HR 0.76, 0.54-1.06). Conclusion: We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX-trastuzumab in clinical practice and point toward a possible benefit of FOLFOX-trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials.

Matèries

Càncer d'estómac, Quimioteràpia

Matèries (anglès)

Stomach cancer, Chemotherapy

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

JIMÉNEZ FONSECA, Paula, CARMONA BAYONAS, Alberto, MARTÍNEZ TORRON, Alba, ALSINA, Maria, CUSTODIO, Ana, SERRA, Olbia, CACHO LAVÍN, Diego, LIMON MIRON, Maria luisa, SAURI, Tamara, LÓPEZ, Flora, VISA, Laura, GRANJA, Mónica, MARTÍNEZ LAGO, Nieves, ARRAZUBI, Virginia, VIDAL TOCINO, Rosario, HERNANDEZ, Raquel, AGUADO, Gemma, CANO, Juana maría, MARTÍN CARNICERO, Alfonso, MANGAS-IZQUIERDO, Montserrat, PIMENTEL, Paola, FERNÁNDEZ MONTES, Ana, MACIAS DECLARA, Ismael, LONGO, Federico, RAMCHANDANI, Avinash, MARTÍN RICHARD, Marta, HURTADO, Alicia, AZKARATE, Aitor, HERNÁNDEZ PÉREZ, Carolina, SERRANO, Raquel, GALLEGO, Javier, On Behalf Of The Agamenon-seom Study Group. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. _Therapeutic Advances in Medical Oncology_. 2021. Vol. 13, núm. 175883592110196. [consulta: 20 de gener de 2026]. ISSN: 1758-8359. [Disponible a: https://hdl.handle.net/2445/179950]

Exportar metadades

JSON - METS

Compartir registre